---
title: Combination of Rituximab and NK Immunotherapy for B Lymphoma
nct_id: NCT02843061
overall_status: COMPLETED
phase: PHASE1, PHASE2
sponsor: Fuda Cancer Hospital, Guangzhou
study_type: INTERVENTIONAL
primary_condition: B-cell Lymphoma Recurrent
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02843061.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02843061"
ct_last_update_post_date: 2019-09-12
last_seen_at: "2026-05-12T07:03:11.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Combination of Rituximab and NK Immunotherapy for B Lymphoma

**NCT ID:** [NCT02843061](https://clinicaltrials.gov/study/NCT02843061)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Fuda Cancer Hospital, Guangzhou
- **Collaborators:** Shenzhen Hank Bioengineering Institute
- **Conditions:** B-cell Lymphoma Recurrent
- **Start Date:** 2016-07-01
- **Completion Date:** 2019-07-01
- **CT.gov Last Update:** 2019-09-12

## Brief Summary

The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.

## Detailed Description

By enrolling patients with B lymphoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Rituximab and natural killer (NK) cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
* Body tumor 1-6, the maximum tumor length \< 5 cm
* KPS ≥ 70, lifespan \> 6 months
* Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

* Patients with cardiac pacemaker
* Patients with brain metastasis
* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
```

## Arms

- **Rituximab and NK immunotherapy** (EXPERIMENTAL) — In this group, the patients will receive regular Rituximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
- **Rituximab** (ACTIVE_COMPARATOR) — In this group, the patients will receive regular Rituximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

## Interventions

- **Rituximab** (DRUG)
- **NK immunotherapy** (BIOLOGICAL) — Each time 10 billion cells, 4 times in all,i.v.

## Primary Outcomes

- **Relief degree evaluated by the RECIST** _(time frame: 3 months)_ — It will be evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST)

## Secondary Outcomes

- **Progress free survival (PFS)** _(time frame: 1 year)_
- **Overall survival (OS)** _(time frame: 3 years)_

## Locations (1)

- Cancer Institute in Fuda cancer hospital, Guangzhou, Guangdong, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.cancer institute in fuda cancer hospital|guangzhou|guangdong|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02843061.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02843061*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*